Center for Breakthrough Medicines‘ headquarters at the Discovery Labs, King of Prussia, Pennsylvania

January 11, 2022 10:41 AM EST

Korean conglomerate SK takes out stake in cell and gene therapy CDMO with plans for a major hiring spree outside Philly

Josh Sullivan

A Pennsylvania CDMO specializing in cell and gene therapy manufacturing is receiving a big influx of cash from a South Korean drugmaker — and it has …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Korean conglomerate SK takes out stake in cell and gene therapy CDMO with plans for a major hiring spree outside Philly

Josh Sullivan

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

Vertex makes money from sickle cell therapy Casgevy

Sana narrows focus again to zero in on diabetes and autoimmune disease

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Ko­re­an con­glom­er­ate SK takes out stake in cell and gene ther­a­py CD­MO with plans for a ma­jor hir­ing spree out­side Philly

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Korean conglomerate SK takes out stake in cell and gene therapy CDMO with plans for a major hiring spree outside Philly